Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Il Science Co., Ltd. (307180:KRX), powered by AI.
Il Science Co., Ltd. is currently trading at ₩6,360. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Il Science Co., Ltd. on Alpha Lenz.
Il Science Co., Ltd.'s P/E ratio is 393.4.
“Il Science Co., Ltd. trades at a P/E of 393.4 (premium valuation) with modest ROE of 4.9%. 3Y revenue CAGR of 19.7% highlights clear growth momentum.”
Ask for details →Il Science Co., Ltd. is a company known for its focus on scientific advancements and healthcare solutions. The company primarily engages in the development and production of diagnostic products and laboratory equipment, playing a critical role in the medical and research sectors. With a strong emphasis on innovation, Il Science Co., Ltd. manufactures a broad range of diagnostic devices that are essential in clinical testing and research laboratories. These products support various sectors, including biotechnology, pharmaceuticals, and healthcare, aiding in the early detection and management of diseases. The company’s contributions are vital for improving patient outcomes and advancing scientific research by providing reliable and accurate diagnostic tools. Il Science Co., Ltd. is recognized for its commitment to quality and technological advancement, significantly impacting the health diagnostics market. Through strategic partnerships and continuous research, the company aims to enhance its product offerings, thus maintaining a strong presence in the global healthcare landscape.
“Il Science Co., Ltd. trades at a P/E of 393.4 (premium valuation) with modest ROE of 4.9%. 3Y revenue CAGR of 19.7% highlights clear growth momentum.”
Ask for details →Il Science Co., Ltd. (ticker: 307180) is a company listed on KRX in the Technology sector (Electronic Components). It has approximately 5 employees. Market cap is $220.8B.
The current price is ₩6,360 with a P/E ratio of 393.36x and P/B of 14.2x.
ROE is 4.89% and operating margin is 6.33%. Annual revenue is $83.5B.